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MitophagyThe leucine rich repeat kinase 2 (LRRK2/dardarin) is implicated in autosomal dominant familial and sporadic
Parkinson's disease (PD); mutations in LRRK2 account for up to 40% of PD cases in some populations. LRRK2 is
a large protein with a kinase domain, a GTPase domain, and multiple potential protein interaction domains. As
such, delineating the functional pathways for LRRK2 and mechanisms by which PD-linked variants contribute
to age-related neurodegeneration could result in pharmaceutically tractable therapies. A growing number of
recent studies implicate dysregulation of mitogen activated protein kinases 3 and 1 (also known as ERK1/2) as
possible downstream mediators of mutant LRRK2 effects. As these master regulators of growth, differentiation,
neuronal plasticity and cell survival have also been implicated in other PDmodels, a set of common cell biological
pathways may contribute to neuronal susceptibility in PD. Here, we review the literature on several major
cellular pathways impacted by LRRK2 mutations – autophagy, microtubule/cytoskeletal dynamics, and protein
synthesis – in context of potential signaling crosstalk involving the ERK1/2 andWnt signaling pathways. Emerg-
ing implications for calcium homeostasis, mitochondrial biology and synaptic dysregulation are discussed in
relation to LRRK2 interactions with other PD gene products. It has been shown that substantia nigra neurons
in human PD and Lewy body dementia patients exhibit cytoplasmic accumulations of ERK1/2 in mitochondria,
autophagosomes and bundles of intracellular ﬁbrils. Both experimental and human tissue data implicate patho-
genic changes in ERK1/2 signaling in sporadic, toxin-based andmutant LRRK2 settings, suggesting engagement of
common cell biological pathways by divergent PD etiologies. This article is part of a Special Issue entitled:
Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is the secondmost commonneurodegener-
ative disorder, affecting approximately 1–2% of the population over the
age of 65 [1]. Clinically, PD is characterized by resting tremor, rigidity,
bradykinesia, and stooped posture. Themajority of thesemotor impair-
ments arise from the loss of dopaminergic neurons in the substantia
nigra pars compacta (SNpc), which results in depletion of dopamine
from the nigro-striatal system. Formation of Lewy bodies (LB),
intracytoplasmic inclusion bodies that contain α-synuclein, often ac-
companies this selective neurodegeneration [2]. Though the
underlying cause of sporadic PD remains unidentiﬁed, exposure to): AG026389 and NS065789 to
sonville, supported in part by
ank, for the unstained sections
olded Proteins, Mitochondrial
BST, Pittsburgh, PA 15213, USA.
ights reserved.environmental toxins and genetic factors have been implicated in PD
pathogenesis.
Higher incidences of sporadic PD have been reported in rural popu-
lations associatedwith agricultural work. This observation suggests that
pesticides and herbicides may contribute to PD [3,4]. Rotenone, a mito-
chondrial complex I inhibitor, is one of the pesticides that has been
linked to PD. It was shown to cause selective degeneration of dopami-
nergic neurons after systemic administration to rats, and is currently
used as a toxin model to study sporadic PD [5]. A toxin previously
shown to induce human parkinsonism is MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine). The oxidized product of MPTP, MPP+ is
selectively taken up by dopaminergic neurons, accumulates in themito-
chondria and inhibits complex I [6]. Both toxins induce mitochondrial
damage, implicating a key role for dysregulated mitochondrial homeo-
stasis in sporadic PD.
Though comprising only a fraction of total PD cases, a genetic compo-
nent to parkinsonian neurodegeneration has become well established
(reviewed in [7]). There are at least 16 PARK loci that have been identi-
ﬁed and are associated with either autosomal recessive or autosomal
dominant PD [8]. Causal mutations have been identiﬁed in a number of
these loci, and the functional consequence of these mutations on the
encoded proteins is an area of intense study. Mutations in the leucine-
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familial PD [9–12]. The biochemistry of LRRK2 has been reviewed else-
where [13,14]. In this review we discuss major cell biologic processes
and signaling pathways thatmay be regulated by LRRK2, and howmuta-
tions in LRRK2may serve to promote neurodegeneration.
2. LRRK2 and Parkinson's disease
The LRRK2 locus was ﬁrst identiﬁed in a Japanese family with auto-
somal dominant parkinsonism by linkage analysis, involving a novel
PARK locus on chromosome 12q12 that was named PARK8 [15]. In
2004, two independent groups cloned the responsible gene and identi-
ﬁed pathogenic mutations in the PARK8 locus [11,16].
LRRK2 is a multidomain, 2527 amino acid (~280 kDa) protein. The
N-terminus consists of an ankyrin-like domain and leucine-rich repeats
(LRR). LRRK2 also contains a Ras of complex (ROC) GTPase domain
adjacent to a C-terminal of ROC (COR) domain that functions as a linker
between the N- and C-terminus of the protein. The kinase domain and a
WD40 domain are present in the C-terminal portion of the protein [17].
The LRRK2 kinase domain shares a close homology with mixed linkage
kinases (MLKs), which comprise a sub-class of the mitogen activated
protein kinase kinase kinase (MAPKKK) family.
Expression analysis by RT-PCR [11] and Northern Blot [16] revealed
that LRRK2 is widely expressed in various tissues and cell types, includ-
ing the brain, lungs, liver, skeletalmuscle and kidneys.Within the brain,
it is expressed in multiple regions, with a high level of expression in the
putamen, where terminals of the substantia nigra region that are vul-
nerable to neurodegeneration in PD project. LRRK2 is predominately lo-
calized in the cytoplasm, where it associates with mitochondria [18],
endoplasmic reticulum, Golgi, microtubules [10] and vesicular struc-
tures such as lysosomes and endosomes [19].
Multiple pathogenicmutations in LRRK2 have been linked to familial
parkinsonism. These include I2020T [12], G2019S [20–22], R1441G [9],
R1441C [11] and Y1699C [16]. The most prevalent mutation is G2019S
in the kinase domain which increases LRRK2 kinase activity and is
estimated to occur in approximately 6–8% of familial and 1–2% of spo-
radic PD cases [23]. LRRK2-G2019S mutants can form inclusion
bodies when expressed in cultured cells or neurons, associated with
neuronal toxicity [24]. The toxic effects of this mutation can be amelio-
rated using the selective LRRK2 inhibitor, LRRK2-IN-1 [25].
Most LRRK2 kinase activity studies have been done in vitro using
generic substrates, such as myelin basic protein (MBP); identifying
in vivo targets of LRRK2 remains an area of active investigation. A num-
ber of proteins represent potential substrates, including: Ezrin/Radixin/
Moesin (ERM) [26], beta-tubulin [27], 4E-BP1 [28] and alpha-synuclein
[29]. In addition to the in vitro analyses of LRRK2 targets, a variety of cell
culture and animal studies indicate that LRRK2 may play a role in the
regulation of cell death, autophagy, the cytoskeleton, protein translation
and cell signaling pathways.
3. The cell biology of LRRK2 and its mutations
3.1. LRRK2 and autophagy
Autophagy is an important catabolic process in which cytoplasmic
components are engulfed into a double membrane vesicle called an
autophagosome, after which they are delivered by fusion events to the
lysosome for hydrolytic degradation [30]. Cells use autophagy to main-
tain protein and organellar integrity on an ongoing basis. Autophagy is
induced in response to starvation [31,32] and other cellular stresses
implicated in a number of neurodegenerative diseases (reviewed in
[33]). In neurons, suppression of basal autophagy results in the accumula-
tion ofmisfolded proteins and neurodegeneration [34,35]. Autophagy is a
common response to injury, but depending on the context, autophagy
induction can be adaptive or maladaptive [36].A number of studies have emerged that implicate a link between
LRRK2 and autophagy regulation, but the exact mechanisms are still
poorly understood. Overexpression of pathogenic LRRK2 mutants
induces autophagosome accumulation in multiple cell types, including
neurons [37,38], neuronal cell lines [39] and kidney cells [40].
The ﬁrst study implicating LRRK2 in the (mis)regulation of autopha-
gy utilized retinoic acid differentiated SH-SY5Y cells to show that the
G2019S mutant of LRRK2, but not the kinase-deﬁcient mutant,
increased autophagosomes in neurites. More mature autophagic vacu-
oles (multivesicular-like bodies and lysosomes) were observed in the
soma [39] suggestive of retrograde trafﬁcking and maturation. RNAi
knockdown of components of the autophagic machinery, LC3 and
Atg7, indicated that the LRRK2-induced neurite retraction is mediated
by autophagy [39], conﬁrming that mutations in LRRK2 regulate the
morphology of neuronal processes in PD [41]. Subsequent studies in
primary neurons demonstrated that Protein kinase A protects against
G2019S- or R1441C-LRRK2-mediated dendrite shorteningby phosphor-
ylating and inactivating LC3, themammalian homolog to the yeast Atg8
autophagy protein [37].
Perturbed calcium homeostasis has been shown to play a role in
LRRK2-induced autophagy. Autophagy induced by overexpression of
wild type or G2019S LRRK2 has been reported to occur through activa-
tion of an NAADP related Ca2+/CaMKK/AMPK pathway [42]. Treatment
with inhibitors of this pathway, such as compound c (AMPK inhibitor),
STO-609 (CaMKK-a/b inhibitor), or chelation of intracellular calcium
with BAPTA-AM abrogates the increase in autophagosome number in-
duced by LRRK2 overexpression [42]. Additionally, deﬁciencies in calci-
um handling lie upstream of dendritic mitophagy, which contributes to
dendrite retraction in primary neurons overexpressing G2019S- or
R1441C-LRRK2 [38]. Inhibition of calcium inﬂux through L-type voltage
gated calcium channels prevents mitochondrial depolarization,
mitophagy and dendrite shortening [38].
It remains controversial whether the autophagosome accumulation
induced by LRRK2 is due to an increase in autophagy induction, inhibi-
tion of autophagic ﬂux, or both. Overexpression of the LRRK2-R1441G in
HEK293 cells caused accumulation of p62 and large autolysosomes, con-
sistent with decreased ﬂux [40]. However, a subsequent study showed
that the LRRK2-mediated increase in p62 could be blocked by a transla-
tion inhibitor [42]. The earlier study also reported that knockdown of
GFP-tagged LRRK2 prevented cell death caused by baﬁlomycin under
starvation conditions. Since baﬁlomycin inhibits late stages of lysosomal
degradation [43], it is unclear how LRRK2 siRNA would be able to re-
store ﬂux through the system, suggesting additional mechanisms of
cytoprotection. In a recent study involving a LRRK2 kinase inhibitor
(LRRK2-IN-1), LRRK2 activity was placed upstream of autophagy initia-
tion. As this highlights a possible role of endogenous LRRK2 in suppress-
ing autophagy initiation, it is possible that either too little or too much
LRRK2 kinase activity may induce autophagy [44].
In vivo studies also suggest that altered LRRK2 expression leads to
dysregulation of autophagy. Lrrk2−/− mice are viable, physically
normal, and have an intact dopaminergic system [45]. However,
alpha-synuclein and ubiquitinated protein accumulation, accompanied
by dysregulation of the autophagy-lysosomal pathway, has been
observed in the kidneys. The observed alterations of autophagic activity
are age-dependent and bi-phasic. At 1 month of age there are no
observable differences, but autophagic activity is enhanced at 7 months,
and then reduced at 20 months [46]. The authors suggest that impaired
clearance of proteins observed in aged mice was due to decreased
recycling of induced autolysosomes and increased accumulation of
autophagic vacuoles.
Transgenic mice expressing LRRK2-G2019S show progressive de-
generation of dopaminergic neurons, as demonstrated by shorter
neurite length and branching, leading to an autophagy-induced reduc-
tion in neurite complexity. This loss of DA neurons, is more pronounced
in older G2019S-LRRK2 transgenic mice than younger transgenic or
wild type mice, and requires a certain level of LRRK2 overexpression
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increased loss of photoreceptors in the retina due to elevated autophagy
caused by upregulation of key autophagy gene, Atg5, compared to wild
type LRRK2 overexpression [48].
LRRK2 may also be a victim of dysregulated autophagy rather than
the perpetrator. Conditional deletion of the essential autophagic gene,
Atg7, in DA neurons caused a presynaptic accumulation of alpha-
synuclein, p62 and LRRK2 proteins in large intracellular inclusions in
the brain [49]. Similarly, there was almost a 4-fold increase in LRRK2
mRNA in Atg5−/−MEFs compared to control cells. These results showed
that dysregulation of autophagy could lead to an abnormal elevation in
expression of LRRK2 [49].
The role that LRRK2 plays in autophagy regulation remains unclear.
However, a large body of evidence suggests that autophagosome accu-
mulation induced by expression of PD-associated mutants contributes
to injury in LRRK2 models of PD. Alterations in calcium handling and
LRRK2 kinase activity have been shown to contribute to this phenotype,
but further investigation is required to unravel the mechanism of
autophagy dysregulation in these models.
3.2. LRRK2 and microtubule dynamics
Cytoskeletal components are important for maintaining the struc-
tural support for neurons, in vesicular biogenesis, organelle or vesicle
transport, and synaptic signaling [50]. Dysfunction in cytoskeleton
dynamics is often associated with neurodegenerative diseases [51,52].
Rotenone, amitochondrial complex I inhibitor,was shown to induce de-
polymerization of microtubules leading to disruption in the transport of
dopamine vesicles and their accumulation in the soma and eventually,
oxidative stress due to the leakage of dopamine from these vesicles [53].
LRRK2 has been shown to co-localize with β-tubulin [10,19] and to
interact directly with α/β tubulin through the ROC GTPase domain
[19,54]. Wild-type and R1441C LRRK2 had similar afﬁnities for α/β
tubulin [19]. Human LRRK2 interacted with β tubulin and preferentially
phosphorylated tubulin from bovine brain, which was enhanced three-
fold by the G2019S mutation [27]. Interestingly, phosphorylated
β-tubulin did not immunoprecipitate with LRRK2 in HEK293 cells de-
spite this interaction. When incubated with microtubule associated
protein-rich medium, G2019S-LRRK2 signiﬁcantly enhanced microtu-
bule assembly/stability. These results suggest that increased phosphor-
ylation of β tubulin by G2019S-LRRK2 mutant results in decreased
microtubule dynamics, affecting the structure of the neurons [27]. Re-
cently, multiple PD associated LRRK2 mutants (R1441C, R1441G,
Y1699C and I2020T) have been shown to form ﬁlamentous structures
that associate with microtubules [55]. This association requires kinase
function and the WD40 domain. Interestingly, the G2019S mutation
did not show any ﬁlament formation [55], raising the possibility of
different pathogenic mechanisms elicited by the mutation that clearly
elevates kinase activity versus the mutations that do not.
The interaction of LRRK2 and tau (amicrotubule-associated protein)
leads to increased phosphorylation of tau and shorter neurite processes
[41]. This phenotype was prevented with the expression of kinase dead
(K1906M) fragment of LRRK2, although caution should be taken due to
the need for further characterization of this fragment. Interestingly, this
interaction and the in vitro phosphorylation of tau by LRRK2 are depen-
dent on tubulin [51]. G2019S- [56] and I2020T- [57], but not R1441C-,
LRRK2 mutants phosphorylated more tau than wild-type LRRK2 [58].
Overexpression of the G2019S PD-associated mutant of LRRK2 led to
tau-positive inclusions in neurons and LRRK2 co-localized with tau in
these inclusions. In Drosophila, expression of G2019S-LRRK2 induced
mislocalization of tau in the dendrites that leads to dendrite degenera-
tion [59]. Tau phosphorylation was dependent on the expression of
LRRK2, as increased LRRK2 expression increased tau phosphorylation,
which was conversely reduced by RNAi knockdown of LRRK2. The
expression level of LRRK2 was inversely correlated with neurite length
[57,58]. Taken together with the autophagy and mitophagy datadiscussed above, it appears thatmultiple LRRK2-associatedmechanisms
may contribute to LRRK2-mediated neurite shortening.
Elongation factor 1A (EF1A), a GTPase that transports aminoacyl-
tRNA to the ribosomes during protein translation and is essential for
cytoskeletal organization [60,61], has also shown to interact with
LRRK2 [62]. Binding of EF1A signiﬁcantly reduced the autophosphoryl-
ation activity of wild type-, G2019S- and R1441C-LRRK2. The microtu-
bule assembly activity of EF1A was shown to be impaired in the
presence of wild-type and G2019S-LRRK2 in an in vitro microtubule
polymerization assay. Phospho-EF1A could not be detected in this
study suggesting that EF1A is not a direct target of LRRK2 [62].
In dopaminergic neurons, either knockdown of LRRK2 [63] or trans-
genic mice expressing LRRK2-G2019S mutations [64] led to shortening
of neurite extensions. Using the KinasE Substrate Tracking and ELucida-
tion screening (KESTREL) approach, moesin, a protein that anchors the
actin cytoskeleton to the plasmamembrane, aswell as ezrin and radixin
were proposed as G2019S-LRRK2 targets [26]. A follow-up study from
the same group, however, failed to detect phosphorylation of ERM pro-
teins in HEK293 cells, even after overexpression of LRRK2-wt or LRRK2-
G2019S [65]. On the other hand, mutant LRRK2-G2019S did enhance
phosphorylation of ERM proteins in another study, which was correlat-
ed with retardation of neurite outgrowth, and inhibition of ERM
phosphorylation was able to rescue the G2019S-phenotype [64]. Data
fromNIH3T3 cells suggest that LRRK2 can directly bind F-actin, affecting
its polymerization and depolymerization in vitro. These discrepancies
suggest that either LRRK2 status modulates ERM phosphorylation
indirectly, or that detection of phosphorylated ERM proteins might be
dependent on experimental conditions. It will be interesting to see if
other groups can detect phospho-ERMs in mammalian neurons.
In summary, current evidence suggests that either too much or too
little LRRK2 activity may contribute to neurite shortening, although ini-
tial studies indicated that LRRK2 knockdown caused elongated neuronal
processes [41]. LRRK2 may interact with and/or phosphorylate or
regulate the phosphorylation of several structural and regulatory
components of the actin cytoskeleton and microtubule network.
Given that neurite shortening is a commonly observed phenotype
in neuronal cells expressing pathogenic LRRK2 mutants, under-
standing these cytoskeletal associations and their possible relation-
ships with autophagy or mitochondrial dynamics may provide
insight into the PD pathogenesis.3.3. LRRK2 and protein translation control
LRRK2 was shown to interact with genes in the TOR/4E-BP pathway
in Drosophila [28]. In the same study, human wild type LRRK2 and an
I2020T mutant were able to phosphorylate 4E-BP1. Eukaryotic 4E-BP1
binds to initiation factor 4E (eIF4E) and inhibits its function,while phos-
phorylation alleviates this inhibition. Phosphorylation of 4E-BP1 by
LRRK2 decreases survival of Drosophila neurons. In contrast, loss of
LRRK2 or gain of 4E-BP1 function rescues pathology in Drosophila
Parkin/PINK1 models [66]. Hence, it has been hypothesized that
increased LRRK2 expression or kinase activity increases protein transla-
tion to a level that overwhelms the cellular degradation machinery,
resulting in accumulation of unwanted proteins [28,66].
However, this interpretation has been challenged by other studies.
While phosphorylation of 4E-BP by LRRK2 can be demonstrated
in vitro, it is a relatively poor substrate [67]. Moreover, increased
phosphorylation was not observed when LRRK2 was overexpressed in
HEK cells. This study suggested that 4E-BP phosphorylation may be an
indirect phenomenon related to p38-mediated cell stress [67]. Similar
results were obtained in another study in which the phosphorylation
status of endogenous 4E-BP1 was not altered in the brains of LRRK2
knockout or mutant LRRK2 transgenic mice, nor were there changes in
idiopathic or G2019S PD patient brains, suggesting that 4E-BP1 is not
a direct substrate for LRRK2 in mammalian systems [68].
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Mitochondrial dysfunction is widely recognized as a contributor to
parkinsonian injury. Common themes observed in multiple genetic or
toxin models include increased reactive oxygen species production,
altered mitochondrial dynamics, decreased mitochondrial membrane
potential, and impaired calciumhomeostasis. The recessive parkinsonian
genes PINK1, Parkin and DJ-1 have been particularly implicated in mito-
chondrial homeostasis, and LRRK2 interacts with these recessive PD
genes in Drosophila [69]. Interestingly, recent studies also implicate
mitochondrial dysfunction in LRRK2 pathogenic mechanisms.
A loss of mitochondrial membrane potential has been reported in
primarymouse cortical neurons, immortalized cell lines, and PD patient
ﬁbroblasts expressing mutant LRRK2 [38,70]. In addition, elevated ROS
and diminished ATP levels have been reported in human ﬁbroblasts
derived from patients with the G2019S pathogenic mutation [71].
Decreased ΔΨm may initiate mitochondrial ﬁssion, and knockdown of
PINK1 limits phosphorylation of Drp1 at Ser637, enabling it to be re-
cruited to mitochondria to facilitate ﬁssion [72,73]. Two recent studies
suggest that overexpression of WT or mutant LRRK2 also leads to mito-
chondrial fragmentation in mouse primary cortical neurons, SH-SY5Y,
and HeLa cells [74,75]. Further, a direct interaction between LRRK2
and Drp1 was described in these reports.
In order to maintain healthy mitochondrial networks, damaged
mitochondria need to be recycled by mitophagy. Parkin and PINK1 are
integrally involved in regulating the selective, autophagic clearance of
mitochondria known as mitophagy [76,77]. We have recently reported
that loss of dendriticmitochondria in G2019S or R1441C LRRK2 neurons
can be reversed by inhibition of autophagy [38]. Interestingly, perturbed
calcium homeostasis was the underlying cause of dendritic mitophagy
induced by mutant LRRK2 expression. Consistent with our ﬁndings,
another group has reported that elevated intracellular calcium levels
are necessary for LRRK2 induced autophagy [42]. Delayed calcium clear-
ance has also been observed following PINK1 knockdown and in cells
expressing mutant PINK1; thus, impaired calcium buffering is a shared
feature of mutant LRRK2 and PINK1-related pathogenic mechanisms
[78–80].
Overexpression of PKA protects against injuries induced by either
PINK1 knockdown [72] or G2019S-LRRK2 expression [37], providing
further evidence that converging signaling cascades contribute to path-
ogenesis in PINK1 and LRRK2 models. Phosphorylation of Drp1 by PKA
appears to be the primary mechanism of protection in PINK1 deﬁcient
cells [72], whereas of phosphorylation of LC3 is involved in PKA-
mediated protection against injury in cells expressing mutant LRRK2
[37]. PINK also regulates phosphorylation of LC3, albeit through indirect
mechanisms, and overexpression ofWT-PINK1 prevents autophagy and
neurite retraction in cells expressing G2019S-LRRK2 (SJ Cherra & CT
Chu, unpublished data).
Aswith other geneticmodels of PD, alteredmitochondrial dynamics,
impairedmitochondrial calcium buffering, elevations in ROS levels, and
decreased ΔΨm have been reported in cells expressing PD-associated
LRRK2 mutants. The parallels that can be drawn between pathogenic
mechanisms in genetic models of PD provide compelling evidence
that aberrant regulation of convergent signaling pathways contributes
to mitochondrial dysfunction.
3.5. Endosomal/synaptic dysregulation in LRRK2 pathogenesis
The cytoskeletal, autolysosomal and protein synthesis effects of
LRRK2 have been shown to affect synaptic vesicle function/dysfunction
and the dynamics of recycling endosomes [81]. In Drosophila, loss of
LRRK2 causes synaptic overgrowth, while its overexpression has oppo-
site effects [82]. LRRK2 protein targets have been proposed in both the
pre- and post-synaptic compartments, namely the microtubule-
binding protein Futsch and the protein translation inhibitor 4E-BP,
respectively. Presynaptic silencing of LRRK2 causes an increase invesicular dynamics within the recycling pool [83]. In the postsynaptic
compartment, mutant LRRK2 promotes calcium overload through
engagement of L-type calcium channels [38] and glutamate receptors
(E Plowey & CT Chu, unpublished data). While the molecular mecha-
nisms underlying these synaptic alterations remain unknown, other
studies indicate that they may reﬂect more general problems with
RAB7L1-related vesicular protein transport and endosomal, lysosomal
and Golgi trafﬁcking [84]. LRRK2 was shown to interact and partially
co-localize with Rab5b. Additionally, altering the levels of LRRK2 ex-
pression canmodulate endocytosis of synaptic vesicles [85]. Interesting-
ly, either overexpression of wild type or PD associated mutants, or
knockdown of LRRK2 was shown to slow down the rate of endocytosis.
Using yeast as a model system, the defect in endocytosis by LRRK2 was
found to be dependent on its GTPase activity [86]. A recent study iden-
tiﬁed EndoA as a direct substrate for LRRK2, and phosphorylation of
EndoA in a Drosophila model system affects the endocytotic process
[87]. The increased demands for autophagy generated by protein aggre-
gation and mitochondrial dysfunction, combined with defects in
endosomal–lysosomal processes, create an imbalance in cellular quality
control mechanisms and promotes autophagic stress [88].
In summary, LRRK2has been shown to play a role inmaintaining ho-
meostasis at the synapse through multiple mechanisms. Interactions
with known regulators of protein translation, vesicular transport, and
autophagy and endocytosis are important for proper synaptic function.
As many of the studies have been performed in Drosophila, further in-
vestigation is needed to determine the role of these mechanisms in
mammalian LRRK2 models of PD.
4. Interactions of LRRK2 with the Wnt signaling pathway
4.1. The Wnt pathway and PD
Wnt (Wingless/Int) signaling pathways have been implicated in the
regulation of neurogenesis and function of mature and post mitotic
neurons [89]. Wnt ligands are extracellular factors that regulate the
differentiation of neuronal stem cells into mature neurons [90]. The
Wnt signaling cascade has three major branches; canonical, non-
canonical/planar cell polarity and Wnt-Ca2+, of which the canonical
pathwayhas been best described [91]. Activation of this pathway results
in stabilization and nuclear recruitment of beta-catenin, which regu-
lates gene expression [92,93].
The Wnt signaling pathway is important to the development of DA
neurons in the midbrain. Wnt1 and Wnt3a were shown to induce
speciﬁcation of committed dopaminergic precursors, whereas, Wnt5a
induced their differentiation by promoting the maturation of Nurr+, a
nuclear receptor essential for the development and maintenance of
DA precursors into DA neurons [94]. Induced expression of Wnt5a in
ventral midbrain neural stem cells generated 10 fold more DA neurons,
and transplantation of these cells in Parkinson's mice model resulted
in functional recovery [95]. Moreover, compared to single KO mice,
Wnt1−/− and Wnt5−/− double knockout mice showed greater loss of
DA neurons and Nurr1+ cells [96]. In the absence of Wnt ligand, Nurr1
associates with LEF1 and functions as a co-repressor. The Nurr1 and
beta catenin interaction is increased upon Wnt-mediated stabilization
of beta-catenin. This disrupts the Nurr1-LEF1 co-repressor complex
and induces the expression of beta-catenin responsive genes [97].
Several key components of Wnt-beta-catenin pathway are down-
regulated in monkeys treated with MPTP [98]. In mice, MPTP treatment
of the ventral midbrain increases Wnt1 expression as well as deregula-
tion of FZD-1 and beta-catenin expression, suggesting that the Wnt
signaling pathway may contribute to neuroprotection against MPTP
toxicity. Aged mice have decreased Wnt1 and loss of beta-catenin,
which is correlated with failure to recover from acute MPTP toxicity
[99]. Pesticide treatment, which induces sporadic PD, alters expression
ofWnt signaling pathway components [100], and inhibitsWnt signaling
through Dkk1 to promote neurodegeneration in mice treated with
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protective in the human neuroblastoma cell line SH-SY5Ywhen treated
with 6-OHDA [102].
4.2. LRRK2-Wnt interactions
LRRK2 andWnt signaling were ﬁrst linked, when mRNA species in-
volved in the Wnt signaling pathway cascade was shown to be
deregulated by knockdown of LRRK2 in SH-SY5Y cells [103]. Similarly,
a systems biology approach revealed that many transcripts in the Wnt
signaling cascade are co-regulated with LRRK2 [104].
The LRRK2 ROC-COR tandem domain was reported to interact with
Dvl-1, an important mediator in Wnt signaling [105]. This interaction
is disrupted by the Y1699C mutation and strengthened by R1441C and
R1728 mutations in LRRK2 [105]. Additionally, LRRK2 functions as a
scaffold where it interacts with components of the beta-catenin de-
struction complex. Once recruited to the plasma membrane, it has
been shown to bind theWnt-corepressor LRP6 upon stimulation. How-
ever, overexpression of LRRK2 itself does not stimulate the Wnt path-
way. Instead, it requires co-expression of Dvl proteins to be stimulated
by Wnt3a. This induction of Wnt signaling is dependent on the kinase
and GTPase activity of LRRK2, as inhibition of kinase activity by
LRRK2-IN-1 or the inactivating K1347A GTPase mutation prevents
Wnt activation [106]. An interaction between LRRK2 and Sgg (the Dro-
sophila homolog of GSK3β), a component of the beta-catenin destruc-
tion complex, has been reported in Drosophila [59]. This would imply
a role for LRRK2, however, in downregulating canonical Wnt signaling,
in contrast to the prior study.
As differential effects among Drosophila and mammalian systems
have been observedwith other PD-linked genes, it would be interesting
to determine if LRRK2 promotes beta-catenin degradation in mammali-
an cells. As the Wnt signaling pathway is important for neurogenesis,Fig. 1. Cell biological pathways implicated in LRRK2-associated pathobiology: intersection with E
lation by inhibition of repressor protein 4E-BP1, and increasedmitophagy contribute to a state of
ERK1/2-dependent autophagy and downregulation of dendritic mitochondria. LRRK2 and ERK
LRRK2 also triggers Wnt-β-catenin and ERK1/2-dependent changes in gene transcription. The a
to ERK1/2-dependent neurite shortening, while altered endosomal/vesicular dynamics affect sy
CK1: Casein kinase 1; Dvl: Dishevelled; eIF-4E: eukaryotic translation inition factor 4E; ERK1/2
synthase kinase 2beta; LRP6: low density lipoprotein receptor-related protein 6; LRRK2: Leucinethe possible role of LRRK2 in regulation of this pathway, and how it is
affected in PD, still needs to be determined. As chemical (kinase speciﬁc
inhibitors) andmolecular tools (knock-out, transgenic animals) become
increasingly available, future research linkingWnt signaling and LRRK2
would be interesting.
5. Interactions of LRRK2 with MAPK/ERK1/2 signaling pathways
5.1. ERK1/2 signaling in parkinsonian toxin models
Extracellular-regulated kinase 1 and 2 (ERK1/2) belongs to themitogen
activated protein kinase (MAPK) family, which also includes c-Jun NH2-
terminal kinase (JNK) and p38 kinase. These MAPKs are serine/threonine
protein kinases that regulate diverse cellular functions such as cell growth,
division, differentiation and cell death [107,108]. LRRK2 has been implicat-
ed in regulatingmultiple branches of theMAPK superfamily, including the
dual speciﬁcity kinases for the p38MAPK and the JNK pathways [109,110].
Activation of ERK1/2 has been shown to be protective as well as
cytotoxic in different cell models. Transient, early activation of ERK1/2
is typically neuroprotective [111], whereas delayed and sustained
ERK1/2 activation promotes neuronal cell death [111–114]. In the 6-
hydroxydopamine (6-OHDA)model, it was found that there is a delayed
phase of ERK1/2 activation that is attributable to mitochondrial ROS
[115]. Interestingly, activated ERK1/2 is observed in midbrain neurons
of human PD and diffuse Lewy body disease patients [116]. A similar in-
crease in activated ERK1/2was observed in tau associated neuropathol-
ogy [117], which can be seen in some families with mutant LRRK2 [11].
Ultrastructural and dual immunoﬂuorescence studies have demonstrat-
ed that activated ERK1/2 is associated with abnormal mitochondria,
autophagosomes, and intracellular ﬁlaments [118]. Sustained ERK1/2
activation has also been shown to promote the autophagic clearance
of mitochondria in neuronal cells [119], and suppress mitochondrialRK1/2 andWnt signaling pathways. Altered endosomal dynamics, increased protein trans-
autophagic/lysosomal stress. LRRK2 promotes increased intracellular calcium and activates
1/2 also regulate microtubule dynamics by phosphorylation of tau, actin and α/β-tubulin.
utophagic, transcriptional and cytoskeletal effects of mutant LRRK2 expression contribute
naptic function. 4E-BP1: translation repressor protein; APC: Adenomatous polyposis coli;
: Extracellular-signal regulated kinase 1/2; ERM: Ezrin-Radixin-Moesin; GSK3β: Glycogen
-rich repeat kinase 2; MT: Microtubule; β-cat: beta catenin.
Fig. 2. Post-mortem analysis of phosphorylated ERK1/2 in a LRRK2G2019S PD/transitional
Lewy body disease (LBD) patient. Note the punctate, cytoplasmic staining of phosphory-
lated ERK1/2 (red chromagen) in pigmented substantia nigra neurons from the G2019S
patient (A). These are similar in appearance and numbers to those previously reported
in a series of sporadic PD/LBD cases [102], whereas this staining pattern was not seen in
the midbrains of control subjects (B). Previous ultrastructural studies revealed phosphor-
ylated ERK1/2 in association with abnormal mitochondria, autophagosomes, and bundles
of intracellular ﬁlaments in PD/LBD substantia nigra neurons [104]. As reviewed in the
text, alterations in mitochondrial homeostasis, autophagy, microtubule dynamics and
ERK1/2-dependent protein expression are observed inmodels of LRRK2-associated patho-
biology, suggesting the involvement of common cell biological pathways among sporadic
and mutant LRRK2-triggered neurodegeneration. Scale = 20 μm.
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ERK1/2 has also been shown to modulate reactive oxygen species
(ROS) [121–123], nitric oxide [124] and calcium (reviewed in [125]).
Thus, ERK1/2 may be involved in several cellular pathways implicated
in LRRK2 pathobiology: autophagy, microtubule dynamics, neurite
shortening, altered mitochondrial calcium regulation and mitophagy.
5.2. LRRK2: the ERK1/2 link
The most common pathogenic mutation associated with LRRK2 is
G2019S, which occurs in theMAPKKK domain of the protein. In the search
for possible LRRK2 substrates, leukocytes from patients carrying the
G2019S mutation were compared to healthy counterparts. Src, a non-
receptor tyrosine kinase that activates both ERK1/2 andp38,was less phos-
phorylated in G2019S mutants. Similarly, HSP27, a downstream target of
p38was also less phosphorylated. However, therewas an increase in phos-
phorylated ERK1/2 in G2019S leucocytes, suggesting that ERK1/2 could be
activated by a different mechanism in these patients [126].
Neurite retraction, a consistent phenotype caused by expression of
pathogenic LRRK2 mutations, is driven by ERK1/2-dependent mecha-
nisms, including autophagy [39]. This suggests that ERK1/2 activation
may contribute to mutant LRRK2 pathogenicity. In contrast, neuropro-
tective effects of wild type LRRK2 against hydrogen peroxide stress
also seemed to be mediated through ERK1/2 signaling in HEK293 and
SH-SY5Y cells [127]. While the G2019S mutant seemed to act through
ERK1/2-dependent mechanisms, other studies reveal that the patho-
genic Y1699C LRRK2 mutant failed to activate ERK1/2 in SH-SY5Y
[127] or SN4741 cell lines [128].
A study using an inducible system conﬁrmed a role for ERK1/2 in
LRRK2-associated pathology. Overexpression of wild type, G2019S and
R1441C LRRK2 increases phosphorylated ERK1/2 in a time dependent
manner, with delayed ERK1/2 activation compared to the wild type in
HEK293 cells. Increased phospho-ERK1/2 levels correlate with induc-
tion of SNCA, which encodes for α-synuclein. LRRK2 also promoted in-
creased phosphorylation of MEK2, an upstream kinase of ERK1/2
[129]. Indeed, either inhibitors of MEK or dominant negative ERK2 pre-
vents G2019S-mediated autophagic neurite shortening [39], and in-
volvement of ERK1/2 was subsequently conﬁrmed in relation to
G2019S LRRK2-induced increases in basal autophagy [130]. In a recent
study using patient derived iPS cells, genetic correction of LRRK2
G2019S mutation signiﬁcantly ameliorated PD associated phenotypes,
which could also be achieved by inhibition of ERK1/2 [131].
6. Conclusions and future direction
Alterations in autophagy, mitophagy, cytoskeletal dynamics, mito-
chondrial function and the balance of protein synthesis and degradation
have been implicated in relation to the normal or pathological func-
tion(s) of LRRK2 (Fig. 1), as well as in sporadic or toxin-based parkin-
sonism. Interestingly, LRRK2 interacts genetically with α-synuclein
and with recessive PD genes. In contrast to α-synuclein, whose normal
expression is predominantly in axon terminals, it is clear that LRRK2
shows both pre-synaptic and post-synaptic effects in neurons.
Moreover, dendrite shortening is a prominent phenotype of neurons ex-
pressing the mutant LRRK2 gene. Future studies are needed to address
the role of the various cell biological processes impacted by LRRK2
expression, including Wnt-related differentiation, in the context of
human neurons affected in PD.
ERK1/2-related cellular pathways may represent a point of mecha-
nistic convergence between toxin-based models of sporadic PD, and
newer studies of pathogenic mutations in LRRK2, which comprise the
most common familial forms of PD (Fig. 1). Various studies have
emerged linking LRRK2 to the ERK1/2 signaling pathway [39,129]. In-
creased mitophagy observed with LRRK2 and associated pathogenic
mutations [38,132] has also been observed when ERK1/2 activity is
modulated [114]. Cytoplasmic granules of phosphorylated ERK1/2 areobserved in the context of both sporadic and G2019S LRRK2-associated
PD patient substantia nigra neurons (Fig. 2) [116,133]. Most studies
have implicated increased kinase activity of LRRK2 in activation of
ERK1/2, which could be prevented by MEK inhibitors. These studies
would place LRRK2 upstream of ERK1/2. However, as ERK1/2 activation
is not universally observed in cells expressing pathogenic LRRK2 mu-
tants, more studies will be required to conﬁrm how LRRK2 interacts
with this pathway. A better understanding of mechanisms by which
ERK1/2 regulates mitochondrial turnover, protein expression and cyto-
skeletal dynamics may add insights for sporadic and familial forms of
PD linked to LRRK2 as well as several recessive PD genes.
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